Document is current
Any future updates will be listed below
-
Authors
Conen, Silke http://orcid.org/0000-0002-2885-4409
Gregory, Catherine J.
Hinz, Rainer http://orcid.org/0000-0002-7808-9207
Smallman, Richard
Corsi-Zuelli, Fabiana http://orcid.org/0000-0001-9202-3987
Deakin, Bill http://orcid.org/0000-0002-2750-962X
Talbot, Peter S. http://orcid.org/0000-0003-3492-0801
-
Funding
Funding for this research was provided by:
RCUK | Medical Research Council (MR/K020803/1, MR/K020803/1, MR/K020803/1, MR/K020803/1, MR/K020803/1)
- License Information
-
More Information
Article History
Received: 6 January 2020
Revised: 9 June 2020
Accepted: 18 June 2020
First Online: 30 June 2020
Compliance with ethical standards
:
: SC has received consultancy fees from Bayer Healthcare LLC. BD reports grants from P1vital and grants and personal fees from Autifony outside the submitted work. PST has received consultancy fees as an Advisory Board member for Galen Limited; Sunovion Pharmaceuticals Europe Ltd; myTomorrows; and LivaNova UK Ltd. Between 2018 and 2020 he was PI on a clinical drug trial sponsored by COMPASS Pathways Ltd, UK. No conflict of interest to declare for CG, FC-Z, RH, or RPS.
